CLAIMS

1. A compound of Formula (I):



Formula (**I**)

Wherein:

R^1, R^2, R^3, R^4, R^5, R^{6a}, R^{6b}, X and Y are as described herein:

X is CH or N;

Y is C, CH or N;

n is 1 or 2;

⎯⎯⎯ is a single or a double bond;

When Y is N or CH and ⎓ represents a double bond, R^2 is absent;

R^1 is selected from H, C_1-C_6alkyl, C_3-C_7cycloalkyl, C(O)OR^7, or S(O)$_2R^7$, wherein C_1-C_6 alkyl, is optionally substituted with one or more halo, hydroxy, or OR^7;

When Y is C and ⎓ represents a double bond, or when Y is CH and ⎓ represents a single bond, then,

R^2 is selected from H, halo, OR C_1-C_4alkyl, wherein the C_1-C_4alkyl is optionally substituted with one or more halo;

R^3 is selected from H, halo, C(O)R^7 orS(O)$_2R^7$;R^4 is selected from H, halo, C_1-C_6alkyl, or C_3-C_7cycloalkyl, wherein the C_1-C_6alkyl, or C_3-C_7cycloalkyl is optionally substituted with one or more halo, amino, hydroxy, alkoxy, or haloalkyl;

R^5 is selected from H, halo, C_1-C_6alkyl, and C_3-C_7cycloalkyl, wherein C_1-C_6alkyl or C_3-C_7cycloalkyl is optionally and independently substituted with one or more halo, alkoxy, or haloalkyl;

R^{6a} is selected from H, halo, hydroxy, CN, CH_2OH, NH_2, C_1-C_6alkyl, C_3-C_7cycloalkyl, OR^7, NR^7R^7, NHR^7, or $NHC(O)R^7$;

R^{6b} is selected from H, CH_2OH, CH_2NH_2, and C_1-C_6alkyl;

R^7 is independently selected from C_1-C_6 alkyl, C_3-C_7cycloalkyl, phenyl, or haloalkyl, , wherein the C_1-C_6alkyl, C_3-C_7cycloalkyl, phenyl, orhaloalkyl is optionally and independently substituted with one or more substituents selected from phenyl, cycloalkyl, alkyl, halo, amino, and hydroxy;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R^1 is selected from H, methyl, ethyl, propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, 2-hydroxyethyl, 2-methoxyethyl, 2,2,2-trifluoroethyl, 2-fluoroethyl, ethylcarboxyl, methylsulfonyl, or cyclopropylmethyl.

3. The compound of claim 1, wherein R^2 is H, halo, or C_1-C_4alkyl, wherein the C_1-C_4alkyl is optionally substituted with one or more halo, alkoxy, or haloalkyl.

4. The compound of claim 1, wherein R^3 is H, halo, $C(O)NR^7R^7$, $C(O)R^7$, $S(O)_2R^7$, .

5. The compound of claim 4, wherein R^3 is selected from acetyl, propionyl, cyclopropyl carbonyl, fluoromethyl carbonyl, difluoromethyl carbonyl, trifluoromethyl carbonyl, methanesulfonyl, ethanesulfonyl, cyclopropanesulfonyl, benzenesulfonyl, or *p*-toluenesulfonyl, .

6. The compound of claim 1, wherein R^4 is selected from H, F, Cl, Br, CH_3, CF_3, ethyl orcyclopropyl,.

7. The compound of claim 1, wherein R^5 is selected from H, Cl, Br, CH_3, CF_3, ethyl, isopropyl, cyclopropyl, cyclobutyl, or phenyl.

8. The compound of claim 1, wherein R^{6a} is selected from halo, hydroxy, CN, CH_2OH, NH_2, C_1-C_6alkyl, C_3-C_7cycloalkyl, OR^7, NR^7R^7, NHR^7, or $NHC(O)R^7$.

o o

9. A compound selected from the group consisting of

(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone;
(S)-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)-2-methylpropan-1-one;
(S)-2,2,2-trifluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;
(S)-2,2-difluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;
(S)-ethyl 3-acetyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indole-1-carboxylate;
(S)-cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
(S)-2,2,2-trifluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)ethanone;
(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-isopropyl-1H-indol-3-yl)methanone;
(S)-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;
(R)-2,2-difluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;
(R)-cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxy-4-methylisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
cyclopropyl(5-(4-(4-((4-hydroxy-4-methylisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone;

(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)methanone;
cyclopropyl(5-(4-(4-((4-hydroxy-4-methylisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)methanone;
(S)-1-(5-(5-chloro-4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)-2,2,2-trifluoroethanone;
(S)-2,2,2-trifluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)-5-methylpyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;
(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)-5-methylpyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone;
(S)-cyclopropyl(1-ethyl-5-(5-fluoro-4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
(S)-cyclopropyl(1-ethyl-5-(5-fluoro-4-(3-((4-hydroxyisoxazolidin-2-yl)methyl)-4-methyl-1H-pyrrol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
(S)-cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)-5-methylpyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
(S)-cyclopropyl(1-(2-fluoroethyl)-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
cyclopropyl(1-(2-fluoroethyl)-5-(4-(4-(((S)-4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)indolin-3-yl)methanone;
(S)-cyclopropyl(5-(4-(3-cyclopropyl-4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-ethyl-1H-indol-3-yl)methanone;
(S)-2-((3-methyl-1-(2-(1-methyl-3-(methylsulfonyl)-1H-indazol-5-ylamino)pyrimidin-4-yl)-1H-pyrazol-4-yl)methyl)isoxazolidin-4-ol;
(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(methylsulfonyl)-1H-indol-3-yl)methanone;
(S)-cyclopropyl(1-ethyl-5-(4-(3-((4-hydroxyisoxazolidin-2-yl)methyl)-4-methyl-1H-pyrrol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone;

(S)-2-((1-(2-(3-chloro-1,2-dimethyl-1H-indol-5-ylamino)pyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methyl)isoxazolidin-4-ol;
(S)-cyclopropyl(1-(2-fluoroethyl)-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
(S)-cyclopropyl(1-(2,2-difluoroethyl)-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone; and
(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)methanone;

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical formulation comprising a compound of claim 1, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

11. Use of a compound or pharmaceutically acceptable salt thereof as defined in claim 1 for preparing a medicament for the treatment of diseases which can be treated by inhibition of the SYK enzyme.

12. A compound or pharmaceutically acceptable salt thereof of claim 1, for use in the treatment of rheumatoid arthritis and osteoporosis, osteolytic diseases and osteopenia.

13. A compound or pharmaceutically acceptable salt thereof of claim 1, for use in the treatment of heme malignancies, particularly Non-Hodgkin’s Lymphomas including follicular (FL), mantle cell lymphoma, capsule cell lymphoma, neutropenia, small lymphocytic lymphoma, chronic lymphocytic lymphoma, Burkitt and diffuse large B cell lymphomas and T-cell lymphoma.